Not Yet RecruitingPhase 2

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

36 participantsStarted 2027-12

Plain-language summary

The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Non-myeloid malignancy diagnosed by cytology/histology
. Receiving and have received at least one cycle of drug therapy with a high myelosuppressive adverse effect, including but not limited to chemotherapeutic agents such as platinum, targeted agents, antibody-coupled drugs, immunosuppressive agents, etc., and are expected to continue such therapy within 8 weeks of enrollment
. ECOG score of 0-2 and an expected survival of 6 months or more.
. Mean hemoglobin \<10.0 g/dL at screening test and one follow-up test (at least one week thereafter during the screening period), with a difference between the two tests of ≤1.0 g/dL
. Total bilirubin \<1.5 x upper limit of normal (ULN) If Gilbert's syndrome (unconjugated hyperbilirubinemia) have a total bilirubin \< 3 x ULN.
. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 x ULN.
. No iron deficiency, TSAT ≥ 20% and ferritin ≥ 100 ng/mL at screening.
. Serum folate and vitamin B12 ≥ lower limit of normal at screening.

Exclusion criteria

. Hematocrit (Hct) ≥ 36 vol% at the screening assessment.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage of responding patient

Timeframe: From baseline to Week 6 or End of Treatment visit

Trial details

NCT IDNCT06075030

SponsorKind Pharmaceuticals LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-12

Contact for this trial

Yusha Zhu, MD, PhD

6467252552 yushazhu@kindpharmaceutical.com

View on ClinicalTrials.gov More Chemotherapy Induced Anemia trials